GSK (LON:GSK) Posts Quarterly Earnings Results

GSK (LON:GSK) issued its quarterly earnings results on Tuesday. The company reported GBX 10.80 EPS for the quarter, Digital Look Earnings reports. GSK had a return on equity of 35.78% and a net margin of 17.78%.

GSK Price Performance

LON:GSK opened at GBX 1,982 on Tuesday. GSK has a one year low of GBX 1,288.61 and a one year high of GBX 2,282. The stock has a market cap of £79.39 billion, a PE ratio of 13.95, a P/E/G ratio of 1.24 and a beta of 0.30. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79. The stock has a 50 day moving average price of GBX 1,933.21 and a 200 day moving average price of GBX 1,989.71.

Analysts Set New Price Targets

Several equities research analysts have issued reports on GSK shares. Citigroup lowered their target price on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Thursday, May 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,950 price target on shares of GSK in a research report on Monday. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of GBX 2,041.43.

Insider Buying and Selling

In related news, insider Vishal Sikka bought 1,266 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, with a total value of £64,173.54. Also, insider Jeannie Lee purchased 802 shares of GSK stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Over the last three months, insiders purchased 7,625 shares of company stock worth $21,347,004. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.